
## Status of Development Pipeline (As of July 24, 2020)

## Main Status of Development Pipelines (Oncology)



Product Name or Development Code (Generic Name)	Mechanism of Action, etc.	Target Disease	Dev	elopm	ent St	age	- Area	In-house / In-license
			I	II	III	Filed		
ONO-7701* (Linrodostat)	IDO1 inhibitor	Bladder cancer			<b>→</b>		JP·KR·TW	Co-development with Bristol-Myers Squibb
ONO-7912 (Devimistat)	Cancer metabolism inhibitor	Pancreatic cancer			$\rightarrow$		KR	Rafael Pharmaceuticals
			$\rightarrow$				JP	
		Acute myeloid leukemia			$\rightarrow$		KR	
ONO-4687* (Cabiralizumab)	Anti-CSF-1R antibody	Pancreatic cancer		<b>-</b>			JP·KR·TW	Co-development with Bristol-Myers Squibb
ONO-4686*	Anti-TIGIT antibody	Solid tumor		<b>→</b>			JP	Co-development with Bristol-Myers Squibb
ONO-4482* (Relatlimab)	Anti-LAG-3 antibody	Melanoma		<b>-</b>			JP	Co-development with Bristol-Myers Squibb
ONO-7807*	Anti-TIM-3 antibody	Solid tumor		<b>-</b>			JP	Co-development with Bristol-Myers Squibb
ONO-4578*	PG receptor (EP4) antagonist	Solid tumor	$\rightarrow$				JP	In-house
ONO-4483* (Lirilumab)	Anti-KIR antibody	Solid tumor	$\rightarrow$				JP	Co-development with Bristol-Myers Squibb
ONO-7475	Axl / Mer inhibitor	Solid tumor*	$\rightarrow$				JP	- In-house
		Acute leukemia	$\rightarrow$				US	
ONO-7911* (Bempegaldesleukin)	PEGylated IL-2	Solid tumor	$\rightarrow$				JP	Co-development with Bristol-Myers Squibb
ONO-7913 (Magrolimab)	Anti-CD47 antibody	Solid tumor	$\rightarrow$				JP	Gilead Sciences

★: Combination with OPDIVO

## Main Status of Development Pipelines (Other than Oncology)

Product Name or Development Code (Generic Name)	Mechanism of Action, etc.	Target Disease	Development Stage				٨٣٥٥	In-house /
			I	I	Ш	Filed	Area	In-license
ONO-5704 / SI-613	Hyaluronic acid-NSAID	Osteoarthritis				$\rightarrow$	JP	Seikagaku
		Enthesopathy		$\rightarrow$			JP	
ORENCIA SC (Abatacept)	T-cell activation inhibitor	Polymyositis / Dermatomyositis			$\rightarrow$		JP	Co-development with Bristol-Myers Squibb
ONOACT for Intravenous Infusion (Landiolol hydrochloride)	Short-active selective $\beta_1$ blocker	Tachyarrhythmia in low cardiac function for pediatric use					JP	In-house
VELEXBRU Tablet (Tirabrutinib)	Bruton's tyrosine kinase (BTK) inhibitor	Pemphigus		<b>-</b>			JP	In-house
ONO-7269	FXIa inhibitor	Cerebral infarction	$\rightarrow$				JP	In-house
ONO-4685	PD-1×CD3 Bispecific antibody	Autoimmune disease	$\longrightarrow$				JP	In-house
ONO-2808	S1P5 receptor agonist	Neurodegenerative disease	$\rightarrow$				EU	In-house
ONO-7684	FXIa inhibitor	Thrombosis	$\longrightarrow$				EU	In-house
ONO-2910	Schwann cell differentiation promoter	Peripheral neuropathy	$\rightarrow$				JP	In-house
FOIPAN Tablet (Camostat mesilate)	Protease enzyme inhibitor	Novel coronavirus infectious disease (COVID-19)	<b>→</b>				JP	In-house